Welcome to our dedicated page for Blue Water news (Ticker: BWVI), a resource for investors and traders seeking the latest updates and insights on Blue Water stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Blue Water's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Blue Water's position in the market.
Psycheceutical Bioscience (OTC PINK:BWVI) is grappling with long-standing regulatory filing deficiencies that hinder its corporate actions, such as name and symbol changes, mergers, and reverse splits. These issues date back over a decade and remain a notable challenge. Despite the difficulties, the company is working with professionals to find a solution and aims to provide updates soon. Executive Chairman and CEO Neilank K. Jha emphasized their commitment to overcoming these challenges and restoring shareholder value.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Psycheceutical Bioscience (OTC: BWVI) is advancing its NeuroDirect™ ketamine topical cream aimed at treating PTSD. Recently, Rick Doblin, founder of MAPS, visited the company's lab to discuss the technology. The NeuroDirect delivery system promises to administer psychedelic compounds non-invasively, potentially minimizing side effects. Preliminary data show that 80% of patients in pre-clinical studies reported significant PTSD relief without psychoactive effects. The company is preparing to initiate clinical trials in Q2 2023. This innovation may improve treatment efficacy and reduce costs for patients.
Psycheceutical Bioscience (OTC: BWVI) announced a pre-clinical study published in Drug Development & Delivery revealing that over 80% of patients reported relief from PTSD symptoms within minutes of using NeuroDirect™ ketamine topical cream. The study highlights the cream's potential effectiveness over traditional systemic ketamine treatments, suggesting it could be more cost-effective. Patients noted improved focus and awareness without adverse psychogenic effects. The innovative delivery method aims to bypass side effects associated with psychedelic compounds, providing a safer, at-home treatment option for mental health disorders.